Initiation of a cohort to define pathogenic Mechanisms, Precision diagnosis And Complications of Thrombotic Microangiopathies: The IMPACT Study (IMPACT)
Grant number: U54 HL185004-01
Principal Investigators
Lead Institution: Johns Hopkins Medicine
Diseases Studied
- Immune thrombotic thrombocytopenia (iTTP)
- Congenital thrombotic thrombocytopenic purpura (cTTP)
- Complement mediated thrombotic microangiopathy (CM-TMA), commonly called atypical hemolytic uremic syndrome (aHUS)
Funding Opportunities
Pilot and Feasibility Research Program
The Thrombotic Microangiopathy (TMA) Rare Disease Clinical Research Network (RDCRN) IMPACT Consortium, supported by a U54 cooperative agreement from the National Institutes of Health (NIH), invites applications for Pilot and Feasibility Projects designed to advance research on thrombotic microangiopathies and related rare disorders.
The objective of this Pilot Grant Program is to stimulate innovative, high-impact research, foster collaboration in the TMA research community, and support projects that leverage existing TMA infrastructure, data, biospecimens, and expertise. Pilot projects are expected to generate preliminary data that will lead to future extramural funding, expanded clinical studies, or translational advances in TMA.
Learn More
Funding Statement
The Initiation of a cohort to define pathogenic Mechanisms, Precision diagnosis And Complications of Thrombotic Microangiopathies: The IMPACT Study (IMPACT) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). IMPACT is funded under grant number U54HL185004 as a collaboration between NCATS, and the National Heart, Lung, and Blood Institute (NHLBI). This website is hosted by the network’s Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, which is funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818.